基于网络药理学和细胞试验探究黄精干预Ⅱ型糖尿病的作用机制OA

To explore the potential mechanism of Polygonatum Rhizome in intervening Type Ⅱ diabetes mellitus(T2DM),network pharmacology and cell experiments were conducted to screen its active components and corresponding targets using TCMSP database,while T2DM related targets were curated from Genecards and Omim databases.Venny tools were utilized to identify the common targets between Polygonatum Rhizome and T2DM.The David database was employed to perform Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)enrichment analysis on these shared targets.Cytoscape software was then utilized to construct an"active component-target-pathway"interaction network.An insulin-resistant HepG2(IR-HepG2)cell model was established to assess the impacts of active components extracted from Polygonatum rhizome on cellular glucose consumption,uptake,and the expression of key targets.The results indicated that 13 active components identified from Polygonatum Rhizome,including baicalein and diosgenin,were were associated with 67 common targets such as protein kinase B(AKT1),tumor protein P53(TP53),mitogen-activated protein kinase(MAPK).These targets were enriched in 154 signaling pathways,including the phosphatidylinositol 3 kinase-protein kinase B(PI3K/AKT)pathway and the advanced glycation end products-receptor for advanced glycation end products(AGE-RAGE)pathway,both critically implicated in diabetes pathogenesis.The main active components of Polygonatum Rhizome were found to enhance glucose consumption and uptake in IR-HepG2 cells to varying degrees and upregulate the expression of AKT1 and PI3K.In conclusion,components such as baicalein and diosgenin may intervene in T2DM by targeting AKT1 and PI3K,thereby regulating the PI3K/AKT signaling pathway.The study provides a scientific foundation for developing Polygonatum Rhizome as a medicinal and edible health product aimed at type Ⅱ diabetes prevention.